Researchers Urge GLP-1 Weight-Loss Rules to Extend Beyond 2.5-mg Drug Use
Updated
Updated · link.springer.com · Aug 26
Researchers Urge GLP-1 Weight-Loss Rules to Extend Beyond 2.5-mg Drug Use
1 articles · Updated · link.springer.com · Aug 26
Summary
A new paper argues GLP-1 and GIP/GLP-1 therapies should be judged by “appropriate weight reduction,” not just whether prescribing complies with rules on approved use and sourcing.
The authors say medically inappropriate use can stem from unsafe dieting and weak supervision as much as from drug toxicity, citing recent tirzepatide cases in Japan involving ketoacidosis or ketosis.
Three reported patients were women aged 21, 21 and 23 without type 2 diabetes; two were nonobese, and two developed ketoacidosis while taking the lowest 2.5-mg weekly dose.
Japan’s reimbursement system illustrates the gap: anti-obesity drugs require a 6-month lifestyle program at specialized institutions, while diabetes-labeled Mounjaro faces fewer restrictions despite being the same molecule as Zepbound.
The paper says success in weight loss should be measured by nutritional and clinical safety—including risks of underweight and undernutrition—not simply by kilograms lost.